215 filings
10-Q
2024 Q1
NVCR
NovoCure Ltd
Quarterly report
2 May 24
7:01am
8-K
NVCR
NovoCure Ltd
2 May 24
Novocure Reports First Quarter 2024 Financial Results
7:01am
DEFA14A
NVCR
NovoCure Ltd
22 Apr 24
Additional proxy soliciting materials
4:02pm
DEF 14A
NVCR
NovoCure Ltd
Definitive proxy
22 Apr 24
4:00pm
PRE 14A
NVCR
NovoCure Ltd
Preliminary proxy
12 Apr 24
4:01pm
8-K
uhpbko1whj1b7
27 Mar 24
Regulation FD Disclosure
7:00am
S-8
k3dcls2zk2nl1 pv
22 Feb 24
Registration of securities for employees
7:11am
8-K
kvyzv kb6betckau12
22 Feb 24
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
7:06am
8-K
0d1xgq6 wylndok
18 Jan 24
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
7:01am
8-K
zxkmdtj f2trkys
9 Jan 24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
7:00am
8-K
wn3xrcu4k11zsin jks
8 Jan 24
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
7:10am
8-K
divhlm fhxb6q
4 Jan 24
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
4:10pm
8-K
mdh3xp45m
28 Nov 23
Regulation FD Disclosure
7:30am
8-K
o3023 oac
26 Oct 23
Novocure Reports Third Quarter 2023 Financial Results
7:03am
8-K
k0cfr warw
28 Aug 23
Regulation FD Disclosure
7:00am
8-K
b3130d421ibmwjuc4f
27 Jul 23
Novocure Reports Second Quarter 2023 Financial Results
7:03am
8-K
g2sni1e
21 Jul 23
Regulation FD Disclosure
8:00am